What are the side effects of Cagrilintide?
The most commonly reported Cagrilintide side effects are mild nausea, reduced appetite, constipation. Most are mild and tend to be dose dependent. It is generally avoided with history of medullary thyroid carcinoma or MEN-2. Human clinical evidence for Cagrilintide is limited, so this reflects reported and observed effects, not a complete safety profile.
Reported Cagrilintide side effects
- Mild nausea
- Reduced appetite
- Constipation
- Fatigue
Who should avoid it
- History of medullary thyroid carcinoma or MEN-2
- Pancreatitis history
- Pregnancy / nursing
Bloodwork worth tracking
- A1C if metabolic context
- Lipid panel
References
- Once-weekly cagrilintide for weight management, Phase 2 trial — Lau DCW et al., Lancet, 2021
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1) — Garvey et al., N Engl J Med, 2025
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial — Enebo et al., Lancet, 2021
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Cagrilintide
Last updated 2026-06-06.